Latest topics | Infection Update

LATEST TOPICS

E-cigarette vapour may increase risk for pneumonia

The use of electronic cigarettes (e-cigarettes) or ‘vaping’ has been marketed as a safer alternative to tobacco cigarette smoking and as a potential smoking cessation tool. However, recent findings published...

The use of electronic cigarettes (e-cigarettes) or ‘vaping’ has been marketed as a safer alternative to tobacco cigarette smoking and as a potential smoking cessation tool. However, recent findings published...

Levofloxacin for the Management of Hospital-Acquired, Ventilator-Associated and Healthcare-Associated Pneumonia (Interview with Prof. Marin H. Kollef)

Question HAP, VAP, and HCAP – Definition and mechanisms Q01 Defining HAP, VAP, and HCAP Q02 Incidence of HAP, VAP, and HCAP Q03 Mechanisms involved in developing HAP...

Question HAP, VAP, and HCAP – Definition and mechanisms Q01 Defining HAP, VAP, and HCAP Q02 Incidence of HAP, VAP, and HCAP Q03 Mechanisms involved in developing HAP...

The Use of Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis (Interview with Prof. Hartmut Lode)

Question AECB – Defining the diagnosis Q01 Defining AECB Q02 Epidemiological profile of AECB Antimicrobial therapy for AECB Q03 Benefits of antimicrobial therapy Q04 Treatment with antibiotics...

Question AECB – Defining the diagnosis Q01 Defining AECB Q02 Epidemiological profile of AECB Antimicrobial therapy for AECB Q03 Benefits of antimicrobial therapy Q04 Treatment with antibiotics...

Effect of Combination of Levofloxacin and Meropenem against Pseudomonas aeruginosa (Supervised by Prof. Kazuhiro Tateda, MD, PhD)

The pathogen Pseudomonas aeruginosa causes a variety of respiratory tract infections which are normally treated with antipseudomal drugs. However, some of these infections fail to respond to antipseudomonal drugs...

The pathogen Pseudomonas aeruginosa causes a variety of respiratory tract infections which are normally treated with antipseudomal drugs. However, some of these infections fail to respond to antipseudomonal drugs...

Viewing Infectious Respiratory Disease (Supervised by Prof. Jiro Fujita, MD, PhD, ACCP)

Viewing Infectious Respiratory Disease begins by examining bacterial secondary infection following influenza virus infections. Influenza patients can develop secondary infections, leading to pneumonia which may be fatal. The...

Viewing Infectious Respiratory Disease begins by examining bacterial secondary infection following influenza virus infections. Influenza patients can develop secondary infections, leading to pneumonia which may be fatal. The...

The Role of Levofloxacin for the Treatment of Respiratory Tract Infections (Highlights of a Special Roundtable Discussion)

Introduction Pharmacodynamics and Pharmacokinetics of Levofloxacin George L. Drusano, MD Professor and Director Division of Clinical Pharmacology Departments of Medicine and Pharmacology Albany Medical College, Albany, NY, USA Results from...

Introduction Pharmacodynamics and Pharmacokinetics of Levofloxacin George L. Drusano, MD Professor and Director Division of Clinical Pharmacology Departments of Medicine and Pharmacology Albany Medical College, Albany, NY, USA Results from...

New Insights in the Treatment of Severe Infections in the Multiple-Drug Resistant Situation (Highlights of the Daiichi Pharmaceutical Co., Ltd. Satellite Symposium to the 11th International Congress on Infectious Diseases)

Introduction Comparative Antimicrobial Susceptibility of Respiratory Tract Pathogens David Felmingham, BSc MSc Dip LSHTM Chief Executive , GR Micro Ltd, London, UK Honorary Senior Lecturer London School of Hygiene and...

Introduction Comparative Antimicrobial Susceptibility of Respiratory Tract Pathogens David Felmingham, BSc MSc Dip LSHTM Chief Executive , GR Micro Ltd, London, UK Honorary Senior Lecturer London School of Hygiene and...

Levofloxacin Stands Above the Rest: A Fluoroquinolone with Both Efficacy and Safety (Highlights of a Special Roundtable Discussion)

Introduction Antimicrobial Resistance Among Streptococcus Pneumoniae: Implications for Therapy Joseph P. Lynch, III Associate Chief Division of Pulmonary and Critical Care Medicine David Geffen School of Medicine at UCLA Los...

Introduction Antimicrobial Resistance Among Streptococcus Pneumoniae: Implications for Therapy Joseph P. Lynch, III Associate Chief Division of Pulmonary and Critical Care Medicine David Geffen School of Medicine at UCLA Los...

New Challenges for Levofloxacin in the Fight Against Infectious Diseases (Interviews with World-Renowned Experts)

Pharmacokinetic/Pharmacodynamic Breakpoints: Time to Consider New Parameters of Antimicrobial Efficacy George L. Drusano, MD Role of Levofloxacin in the Treatment of Rhinosinusitis Michael D. Poole, MD, PhD Role of...

Pharmacokinetic/Pharmacodynamic Breakpoints: Time to Consider New Parameters of Antimicrobial Efficacy George L. Drusano, MD Role of Levofloxacin in the Treatment of Rhinosinusitis Michael D. Poole, MD, PhD Role of...

New Era for the Treatment of Respiratory Tract infections (Daiichi Pharmaceutical Co., Ltd., Special Interview)

Introduction Regional Resistance Situation in the World Doctor Reuben Grneberg Director of GR Micro Ltd., London,UK The Role of Levofloxacin in Community-acquired Pneumonia Professor Lionel A. Mandell Professor of Medicine,Chief...

Introduction Regional Resistance Situation in the World Doctor Reuben Grneberg Director of GR Micro Ltd., London,UK The Role of Levofloxacin in Community-acquired Pneumonia Professor Lionel A. Mandell Professor of Medicine,Chief...

POPULAR ARTICLES